Adial Pharmaceuticals (ADIL)
(Delayed Data from NSDQ)
$0.35 USD
0.00 (-0.43%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $0.35 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADIL 0.35 0.00(-0.43%)
Will ADIL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ADIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADIL
All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy
Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why
ADIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know
Other News for ADIL
Is ADIL likely to continue higher? Stochastic Buy Signal shows up after rising 1.3%
Narrow Range Bar appears for ADIL after 0.0% move
MACD Bullish Signal Line Cross appears for ADIL after 0.86% move
Adial Pharmaceuticals Advances AD04 with FDA Support
Adial Pharmaceuticals (ADIL) Moves Forward with FDA Guidance on AD04 Phase 3 Trial